Absci (NASDAQ:ABSI - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
Several other brokerages also recently commented on ABSI. Lifesci Capital initiated coverage on shares of Absci in a report on Wednesday, September 9th. They set an "outperform" rating for the company. Guggenheim lowered their price target on shares of Absci from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Monday, November 16th. KeyCorp raised their price objective on shares of Absci from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, October 16th. JPMorgan Chase & Co. boosted their price objective on Absci from $14.00 to $15.00 and gave the stock an "overweight" rating in a report on Monday, October 12th. Finally, Jefferies Financial Group initiated coverage on Absci in a research report on Thursday, October 29th. They issued a "buy" rating and a $14.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $14.90.
Check Out Our Latest Research Report on Absci
Absci Trading Down 8.0%
ABSI opened at $7.51 on Friday. Absci has a 1-year low of $2.24 and a 1-year high of $12.54. The stock's fifty day simple moving average is $9.58 and its 200 day simple moving average is $6.93. The stock has a market cap of $1.30 billion, a PE ratio of -9.51 and a beta of 2.22.
Absci (NASDAQ:ABSI - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting analysts' consensus estimates of ($0.19). Absci had a negative net margin of 8,451.31% and a negative return on equity of 61.60%. The firm had revenue of $0.30 million during the quarter, compared to analysts' expectations of $0.66 million. Equities analysts forecast that Absci will post -0.76 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ABSI. Integrated Wealth Concepts LLC bought a new position in Absci during the second quarter worth $53,000. Sterling Capital Management LLC increased its stake in Absci by 433.7% in the third quarter. Sterling Capital Management LLC now owns 4,622 shares of the company's stock valued at $50,000 after purchasing an additional 3,756 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Absci in the third quarter valued at $94,000. Essential Partners LLC raised its holdings in shares of Absci by 113,850.0% during the first quarter. Essential Partners LLC now owns 9,116 shares of the company's stock valued at $27,000 after purchasing an additional 9,108 shares during the period. Finally, Principal Financial Group Inc. acquired a new position in shares of Absci during the first quarter valued at about $31,000. 52.05% of the stock is currently owned by institutional investors.
Absci Company Profile
(
Get Free Report)
Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Absci, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.
While Absci currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.